Our Blog

 

Redefining a Healthful Diet: New Results from the Largest Observational Study Ever Conducted on Nutrition and Heart Health Challenge Current Advice

By Kevin Maki PhD | Oct 9, 2017 | 0 Comments

Redefining a Healthful Diet: New Results from the Largest Observational Study Ever Conducted on Nutrition and Heart Health Challenge Current Advice By Orsolya M. Palacios, RD, PhD and Kevin C. Maki, PhD Background Cardiovascular disease is a major cause of morbidity and mortality worldwide.  Its relationship to healthful diet and lifestyle practices has been an…

Read More
CVD-REAL

CVD-REAL Results Suggest that Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors are, Indeed, Real

By Kevin Maki PhD | Jul 24, 2017 | 0 Comments

CVD-REAL Results Suggest that Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors are, Indeed, Real By Kevin C Maki, PhD  Background In 2015, the release of the Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial results generated significant surprise and controversy.1 The investigators randomly assigned 7,020 patients with type 2 diabetes…

Read More
FOURIER

Putting the FOURIER Findings in Perspective

By Kevin Maki PhD | Jul 20, 2017 | 0 Comments

Putting the FOURIER Findings in Perspective By Kevin C Maki, PhD Background and Methods Earlier this year the results from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial were published in the New England Journal of Medicine1 in conjunction with their presentation at the American College of Cardiology…

Read More
Changes in Diet Quality and Mortality

Changes in Diet Quality and Mortality

By Kevin Maki PhD | Jul 16, 2017 | 0 Comments

Changes in Diet Quality and Mortality By Kevin C Maki, PhD Background Sotos-Prieto and colleagues from the Departments of Nutrition and Epidemiology at Harvard University published an analysis of the relationships between changes in diet quality scores and mortality [all-cause, cardiovascular (CV), and cancer] in a recent issue of the New England Journal of Medicine.1 …

Read More
CETP Inhibitor

Another CETP Inhibitor Fails to Show Cardiovascular Benefit, Despite Reducing LDL Cholesterol and Raising HDL Cholesterol: Implications of the ACCELERATE Trial

By Kevin Maki PhD | Jul 12, 2017 | 0 Comments

Another CETP Inhibitor Fails to Show Cardiovascular Benefit, Despite Reducing LDL Cholesterol and Raising HDL Cholesterol: Implications of the ACCELERATE Trial   By Kevin C Maki, PhD Cholesteryl ester transfer protein (CETP) is an enzyme that modulates the transfer of cholesterol esters from high-density lipoprotein (HDL) particles to apolipoprotein (apo)-B containing particles, including very-low-density lipoprotein (VLDL)…

Read More
Health Effects of Low-Calorie Sweeteners

Debates Rage on About the Health Effects of Low-Calorie Sweeteners – Newly Published Study Shows No Effect of Sucralose on Carbohydrate Metabolism

By Kevin Maki PhD | Jul 11, 2017 | 0 Comments

Debates Rage on About the Health Effects of Low-Calorie Sweeteners – Newly Published Study Shows No Effect of Sucralose on Carbohydrate Metabolism   By Kevin C Maki, PhD A study published recently in the journal Regulatory Toxicology and Pharmacology by Grotz and colleagues investigated the effects of sucralose consumption on glucose homeostasis in healthy men and…

Read More
MB Clinical Academy

MB Clinical Academy Releases its First Two Educational Programs

By Mary R Dicklin PhD | Jul 9, 2017 | 0 Comments

MB Clinical Academy Releases its First Two Educational Programs MB Clinical Academy produces educational materials to help clinicians, clinical research professionals and students more effectively manage the cardiometabolic health of their patients/clients, and to understand the strengths and limitations of the available evidence, including gaps that can be filled with future studies. We have just…

Read More
Mendelian Randomization

Mendelian Randomization – Nature’s Clinical Trial – is Providing New Insights About the Causes and Potential Treatments for Cardiometabolic Diseases

By Kevin Maki PhD | Jul 6, 2017 | 0 Comments

Mendelian Randomization – Nature’s Clinical Trial – is Providing New Insights About the Causes and Potential Treatments for Cardiometabolic Diseases By Kevin C. Maki, PhD In a recent issue of JAMA Cardiology, Lyall and colleagues1 report that a score based on 97 genetic variants related to body mass index (BMI) was associated with increased risks…

Read More
Reducing Risks for Cardiovascular Disease Events

Results From a Systematic Review and Network Meta-Analysis Suggest that Lower Systolic Blood Pressure Targets Are More Effective for Reducing Risks for Cardiovascular Disease Events and Mortality

By Kevin Maki PhD | Jul 2, 2017 | 0 Comments

Results From a Systematic Review and Network Meta-Analysis Suggest that Lower Systolic Blood Pressure Targets Are More Effective for Reducing Risks for Cardiovascular Disease Events and Mortality Clinical trials have documented that lowering blood pressure reduces cardiovascular disease (CVD) and early death.1 However, the optimal target(s) for reduction of systolic blood pressure (SBP) are uncertain.1-4…

Read More
Dr. Ralph Defronzo Interview

Dr. Ralph Defronzo Interview

By Kevin Maki PhD | Jun 27, 2017 | 0 Comments

Dr. Ralph Defronzo Interview Dr. Ralph Defronzo Interview Steve Freed, RPh, CDE from Diabetes in Control conducted a terrific interview with Ralph DeFronzo, MD, who is an endocrinologist and Deputy Director of the Texas Diabetes Institute.  Dr. DeFronzo has been a pioneer in conducting studies to elucidate the pathophysiology of type 2 diabetes mellitus, and…

Read More